Oxiwear‘s wearable medical device, which continuously tracks oxygen levels in people with pulmonary hypertension (PH) and other heart or lung conditions, will now be covered by Medicare and certain private insurance providers in the U.S., the company announced. The…
Discussion
In a recent column, I shared something I’d been too stubborn to say before: Pushing through fatigue with pulmonary hypertension (PH) almost always costs me more than it gives. The harder I push, the harder I crash. After that column, several readers reached out to say they sometimes…
Discussion
Enrollment is complete in the Phase 2 APEX trial of TX45, Tectonic Therapeutic‘s experimental drug for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), the company reports. “Reaching full enrollment in our APEX Phase 2 clinical trial represents a critical milestone for our TX45 clinical development program…
Discussion
A gene called NDRG1 may help drive blood vessel remodeling seen in chronic thromboembolic pulmonary hypertension (CTEPH) by shifting smooth muscle cells toward a scar-forming state, a study found. “NDRG1 and related key gene axes may serve as potential therapeutic targets for CTEPH,” researchers wrote. The study, “Single-cell transcriptomics…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
